Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

[1] Vallabhajosula S(2014)99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer J Nucl Med Off Publ Soc Nucl Med 55 1791-8

[2] Nikolopoulou A(2015)Initial evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging of prostate cancer Mol Imaging Biol Off Publ Acad Mol Imaging 17 565-74

[3] Babich JW(2015)The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 42 197-209

[4] Osborne JR(2016)Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer Semin Nucl Med 46 405-18

[5] Tagawa ST(2016)The rise of PSMA ligands for diagnosis and therapy of prostate cancer J Nucl Med Off Publ Soc Nucl Med 57 79S-89S

[6] Lipai I(2013)First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer J Nucl Med Off Publ Soc Nucl Med 54 380-7

[7] Szabo Z(2009)Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer Cancer Res 69 6932-40

[8] Mena E(2016)New strategies in prostate cancer: Prostate-Specific Membrane Antigen (PSMA) ligands for diagnosis and therapy Clin Cancer Res Off J Am Assoc Cancer Res 22 9-15

[9] Rowe SP(2005)Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen J Nucl Med Off Publ Soc Nucl Med 46 850-8

[10] Plyku D(2004)Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer J Clin Oncol 22 2522-31

[1] Vallabhajosula S(2014)99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer J Nucl Med Off Publ Soc Nucl Med 55 1791-8

[2] Nikolopoulou A(2015)Initial evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging of prostate cancer Mol Imaging Biol Off Publ Acad Mol Imaging 17 565-74

[3] Babich JW(2015)The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 42 197-209

[4] Osborne JR(2016)Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer Semin Nucl Med 46 405-18

[5] Tagawa ST(2016)The rise of PSMA ligands for diagnosis and therapy of prostate cancer J Nucl Med Off Publ Soc Nucl Med 57 79S-89S

[6] Lipai I(2013)First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer J Nucl Med Off Publ Soc Nucl Med 54 380-7

[7] Szabo Z(2009)Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer Cancer Res 69 6932-40

[8] Mena E(2016)New strategies in prostate cancer: Prostate-Specific Membrane Antigen (PSMA) ligands for diagnosis and therapy Clin Cancer Res Off J Am Assoc Cancer Res 22 9-15

[9] Rowe SP(2005)Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen J Nucl Med Off Publ Soc Nucl Med 46 850-8

[10] Plyku D(2004)Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer J Clin Oncol 22 2522-31